Northern Mariana Islands vs Tonga: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Northern Mariana Islands
0.6%
in 2024
Tonga
0.6%
in 2024
Northern Mariana Islands rank
60th
Tonga rank
60th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Northern Mariana Islands
- Tonga
How they compare
Northern Mariana Islands currently reports 0.6% against 0.6% in Tonga, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Northern Mariana Islands ahead.
Northern Mariana Islands ranks 60th and Tonga ranks 60th of 246 countries.
Across the 2 decades both report, Northern Mariana Islands averaged higher in 1 and Tonga in 1.
Head to head by decade
| Decade | Northern Mariana Islands | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.2% | 1.1% | 0.1% | Northern Mariana Islands |
| 2020s | 0.7% | 0.7% | 0.1% | Tonga |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Northern Mariana Islands or Tonga?
- Northern Mariana Islands, at 0.6% against 0.6% in Tonga as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Northern Mariana Islands and Tonga?
- 0.0%, with Northern Mariana Islands ahead.
- How many years of comparable data are there for Northern Mariana Islands and Tonga?
- 10 years are reported by both, from 2015 to 2024.
- How do Northern Mariana Islands and Tonga rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Northern Mariana Islands ranks 60th and Tonga ranks 60th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.